 Enabling tech is likely to continue driving Globus Medical Incs NYSE:GMED market share gains in 2022, according to BofA Securities. The Globus Medical Analyst: Craig Bijou upgraded the rating for Globus Medical from Underperform to Buy, while raising the price target from 55 to 80. 